Skip to the lineages
Regenerative Medicine

What Is the FDA Approval Status of Muse Cell Therapies?

Published November 16, 2026

Protocol: 7 steps in this guide
  1. What counts as a Muse product
  2. An experimental study is not an approved license
  3. Searching FDA's records by name
  4. Checking the indication and other pathways
  5. Ryoncil is a different, non-Muse product
  6. Other countries are separate
  7. Recording a dated status check

FDA’s list of approved cellular and gene therapy products (content current as of October 30, 2026, checked on November 16, 2026) does not include any product named as a Muse cell therapy. The only mesenchymal stromal cell product on that list is Ryoncil, which is not a Muse cell product and is approved for a pediatric transplant complication. Muse cells have been tested in early human research, including a trial in Japan run under a protocol approved by Japan’s regulator, but research activity is not U.S. approval. Because approvals change, status should be checked against FDA’s own records for an exact product name on the day you need it.

What counts as a Muse product

“Muse” refers to multilineage-differentiating stress-enduring cells, a small fraction of mesenchymal stromal cells identified in the laboratory by the marker SSEA-3, as described in a 2025 review in the Journal of Translational Medicine, Hierarchical therapeutic potential in the mesenchymal stem cell landscape. A Muse product is a specific, manufactured preparation with its own name. In the one published human spinal cord injury trial, the product was called CL2020. A clinic using the word “Muse” for a different preparation is not offering that tested product. How these cells are identified is covered in how Muse cells are identified in laboratory samples.

An experimental study is not an approved license

The 2024 trial by Koda and colleagues in Stem Cell Research & Therapy, Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury, was a 10-person single-arm study. Its authors state that their protocol “was approved by the PMDA,” Japan’s Pharmaceuticals and Medical Devices Agency, and that efficacy could not be concluded without a control group. Approval of a trial protocol permits a study to run; it does not license a product for sale. The trial’s findings are covered in what research shows about Muse cells for spinal cord injury.

Searching FDA’s records by name

For a product claimed to be an FDA-licensed biologic, two FDA sources are the starting point:

Search for the exact trade name and the proper name the clinic gives you, not just “Muse” or “stem cells.” The general method is covered in how you can tell whether a regenerative medicine product is FDA-approved.

Checking the indication and other pathways

A license applies to a named product for named uses. Even a licensed product is approved only for the indication on its label. Some cell and tissue products are regulated through other pathways, and FDA’s framework for the regulation of regenerative medicine products refers to the agency’s “risk-based, flexible regulatory framework,” and its guidance applies criteria such as minimal manipulation and homologous use to each product. Absence from a biologics database is therefore a reason to ask which pathway the clinic claims, not by itself a legal verdict. FDA’s patient and consumer information on regenerative medicine therapies also notes that registration with FDA, or listing on ClinicalTrials.gov, “does not mean the product is legally marketed.”

Ryoncil is a different, non-Muse product

Ryoncil (remestemcel-L-rknd), made by Mesoblast, Inc., is listed on FDA’s Ryoncil product page with this indication: “Indicated for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.” It is a culture-expanded donor bone marrow stromal cell product. Its approval belongs to that product and that indication. It cannot be used to suggest that Muse cells, or any other stromal cell product, are approved for anything.

Other countries are separate

A product’s status in Japan or any other country is decided by that country’s regulator and does not carry over to the United States. A clinic that cites approval or permission abroad is describing a foreign status; ask whether the product has any U.S. FDA approval or is being given under a U.S. investigational new drug application, as explained in what it means when an FDA investigational new drug application is in effect.

Recording a dated status check

Because lists change, write down what you checked and when:

Field Entry
Date checked
Exact product name given by the clinic
Manufacturer
Found in FDA's approved cellular products list?
Found in the Purple Book?
Approved indication, if found
Pathway the clinic claims (BLA, IND, other)

For reference, a check on November 16, 2026 of FDA’s approved cellular and gene therapy products list found a table of 55 product entries, with Ryoncil as the only stromal cell product and no product named as Muse cells or CL2020.

On the dated check above, no Muse cell therapy appears among FDA’s approved cellular and gene therapy products, and Ryoncil’s approval belongs to a different product, so any claim that a Muse treatment is FDA-approved should be verified against FDA’s records by exact product name and indication.

Cells linked to this one

This guide leads on to

Lineage F: Stem Cell Clinical Evidence and Regulatory Boundaries

What readers added

Add a remark

Your email address will not be published. Required fields are marked *